Funded by Department of Health and Human Services - National Institutes of Health Subcontracts
Funding Years: 2014 - 2018
This five-year prevention trial proposes to test an anti-amyloid drug in cognitively normal older volunteers who are at increased risk of developing late-onset Alzheimer’s because they inherited two copies of the APOE4 allele, the best known genetic risk for late-onset disease. The treatment, which has not yet been selected, will be tested in this randomized, controlled clinical trial at multiple sites. Participants will be assessed through cognitive tests, brain imaging and cerebrospinal fluid measurements to evaluate whether the drug impacts amyloid, other biological measurements and the memory and thinking problems related to the disease. The study will test the role of amyloid in the development of Alzheimer’s and will, through imaging and biomarker techniques, help identify faster ways to evaluate other promising prevention therapies in the future. It is anticipated that the study will also be supported with private funding.
PI(s): J. Scott Roberts